[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals announces FDA approval of DAYBUE STIX, a new powder formulation for Rett syndrome. The stock is trading near a 52-week high, bolstered by strong Q3 earnings and positive trial results.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. is a healthcare company focused on treatments for neurological and related disorders.
Acadia Pharmaceuticals Inc. uses the ticker $ACAD for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Acadia Pharmaceuticals Inc. (ACAD) social dominance is up XXXXXX% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) Galaxy Score™ is up XXXXX% from the previous week.
- Acadia Pharmaceuticals Inc. (ACAD) sentiment is up XX% from the previous week.
- Acadia Pharmaceuticals Inc. Price hit a 52-Week high of $XX for the hour
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock is trading near a 52-week high, supported by strong Q3 earnings and positive trial results for trofinetide, with analyst upgrades further bolstering confidence, despite some observed short-term price volatility.
24-Hour: XXXX% 7-Day: -XXXX% 30-Day: XXXXX%
1-Year High: $XXXXX on 2025-12-05
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
Acadia Pharmaceuticals Inc. (ACAD) is currently AltRank #959 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX -XX
X Month: XXX -XXX
X Months: XXX +296
X Year: XXX +192
1-Year High: XXXXX on 2025-07-11
1-Year Low: XX on 2025-01-01
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +6
X Month: XX -XX
X Months: XX -XX
X Year: XX -XX
1-Year High: XX on 2025-05-16
1-Year Low: XX on 2025-06-01
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
X Week: XXXXX -XX%
X Month: XXXXXXX +78%
X Months: XXXXXXXXX +9%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-09-24
1-Year Low: XXX on 2025-05-03
Engagements by network (24h): TikTok: XX X: XXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX +5.30%
X Month: XXX +24%
X Months: XXXXX +19%
X Year: XXXXX -XX%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-05-03
Mentions by network (24h): TikTok: XX X: XXX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Acadia Pharmaceuticals Inc. (ACAD) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
X Week: XXX +9.40%
X Month: XXX +31%
X Months: XXXXX +63%
X Year: XXXXX +165%
1-Year High: XXX on 2025-06-29
1-Year Low: XX on 2025-05-03
The most influential creators that mention Acadia Pharmaceuticals Inc. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Andre_AGTC | X | XXXXX | X | XXX |
| @_le_Lounge | X | XXXXX | X | XX |
| @MarcJacksonLA | X | XXXXX | X | X |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% +17%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% -XX%
1-Year High: XXX% on 2025-04-23
1-Year Low: XX% on 2025-02-01
Most Supportive Themes:
- Positive Trial Results: (45%) Acadia Pharmaceuticals announced positive Phase X trial results for trofinetide in Rett syndrome.
- Analyst Upgrades and Strong Earnings: (30%) Strong earnings and analyst upgrades have driven ACAD to a 52-week high.
Most Critical Themes:
- Price Volatility: (10%) The stock has experienced price fluctuations, with a 24-hour change of -XXXX% and varying performance over longer periods.
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.01%
X Month: XXXXXX% -XXXXXX%
X Months: XXXXXX% -XXXXXX%
X Year: XXXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-01-06
1-Year Low: XXXXX% on 2025-10-22
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXXXX% on 2025-08-27
1-Year Low: XXXXXXX% on 2025-04-29
Market Cap: $XXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$1.50%
X Month: $XXXXXXXXXXXXX +$15%
X Months: $XXXXXXXXXXXXX +$24%
X Year: $XXXXXXXXXXXXX +$60%
1-Year High: $XXXXXXXXXXXXX on 2025-12-05
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08
Top Acadia Pharmaceuticals Inc. Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$ACA $ACAD ⚠👀 Guys Don't miss the next move in a few hours 💸➡"
X Link @Signal_Trader08 2025-12-13T12:48Z XX followers, X engagements
"$ACAD FDA approved Daybue Stix a powder mixed into an oral solution to treat Rett syndrome in patients ages two and older. The new dye and preservative-free formulation is expected to have the same safety and effectiveness as the current Daybue oral solution"
X Link @MaisaCorp 2025-12-12T20:24Z 3158 followers, XXX engagements
"$ACAD -XXXX% today as Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome More Info:"
X Link @OzmosiHealth 2025-12-12T15:57Z 3023 followers, XXX engagements
"$ACAD Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome -"
X Link @MarcJacksonLA 2025-12-12T15:10Z 7639 followers, XXX engagements